McKenna Mark C. — SEC Form 4 filings
SEC reporting owner CIK 1749623. 13 Form 4 filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-02-05 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 20,000 shares, $990,775 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: purchase of 12,500 shares @ $49.85 ($623,125) in Apogee Therapeutics, Inc., filed 2024-12-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. (APGE) | Director | 5 | 2 legs · 20,000 sh · $990,775 | — | 8 |
| NewAmsterdam Pharma Co N.V. (NAMS) | Director | 3 | — | — | 5 |
| Spyre Therapeutics, Inc. (SYRE) | Director | 3 | — | — | 3 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | — | 1 | — | — | 2 |
| Freenome, Inc. (FRNM) | — | 1 | — | — | 2 |
Form 4 filings — McKenna Mark C.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Apogee Therapeutics, Inc. (APGE) | Disposition to issuer (D): 20,000 · Disposition to issuer (D): 150,000 (derivative) · Disposition to issuer (D): 10,370 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative) | EDGAR |
| 2026-07-22 | 4 | Freenome, Inc. (FRNM) | Conversion (C): 30,000 · Conversion (C): 30,000 (derivative) | EDGAR |
| 2026-06-11 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 3,400 · Grant/award (A): 15,300 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | BridgeBio Oncology Therapeutics, Inc. (BBOT) | Option exercise (M): 30,000 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 14,461 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 6,960 · Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2024-12-16 | 4 | Apogee Therapeutics, Inc. (APGE) | Purchase (P): 7,500 @ $49.02 · Purchase (P): 12,500 @ $49.85 | EDGAR |
| 2024-07-19 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 72,500 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 10,370 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1749623 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →